Core Viewpoint - The news highlights the rise of Fan Daidi, the new vice president of Northwest University, as a prominent figure in the business world, particularly in the biotechnology sector, due to her significant stake in the listed company, Juzhi Biotechnology, which has achieved substantial market value and success in the industry [1][4]. Company Overview - Juzhi Biotechnology, co-founded by Fan Daidi and her husband Yan Jianya in 2001, has successfully commercialized human-like collagen through genetic engineering, becoming a model for industry-academia collaboration [3]. - As of 2017, Juzhi Biotechnology had established 11 production lines, with its products being used in over 1,000 hospitals across seven countries and regions, achieving cumulative terminal sales of nearly 10 billion yuan [3]. Market Performance - Juzhi Biotechnology went public on the Hong Kong Stock Exchange in November 2022, with Fan Daidi listed as a co-founder and chief scientific officer [3]. - As of May 12, 2023, Juzhi Biotechnology's market capitalization was approximately 836 billion HKD (about 773 billion yuan), contributing significantly to the combined market value of nearly 900 billion yuan for both Juzhi Biotechnology and another listed company, Xi'an Triangle Defense [4]. Leadership and Governance - Fan Daidi was appointed as the vice president of Northwest University on April 1, 2025, after serving in various leadership roles within the university [4]. - The appointment of Fan Daidi complies with the management regulations for leadership personnel in public institutions in Shaanxi Province, confirming her eligibility for the role [4].

截至2025年5月20日 09:35，恒生医疗保健指数(HSHCI)强势上涨2.69%，成分股三生制药(01530)上涨33.93%，欧康维视生物-B(01477)上涨7.44%，再鼎医药 (09688)上涨6.39%，石药集团(01093)，诺诚健华(09969)等个股跟涨。恒生医疗ETF(513060)高开高走上涨2.48%，冲击3连涨。最新价报0.50元。流动性方 面，恒生医疗ETF盘中换手2.6%，成交2.66亿元。拉长时间看，截至5月19日，恒生医疗ETF近1月日均成交12.37亿元，居可比基金第一。 湘财证券指出，近期在国家鼓励创新大背景下创新药产业链表现活跃，虽然医药工业复苏仍有待验证，行业受医保控费压力仍在，但多层次的支付体系正在 建立，医疗需求的刚性将共同推动行业企稳回升，建议关注高成长及预期改善两大方向，具体而言：（1）高成长：医药外包服务中的ADCCDMO、减肥药 产业链多肽CDMO等方向公司。（2）预期改善：盈利能力有望触底回升的第三方检验医学实验室，消费医疗中的眼科及口腔等方向的公司。 恒生医疗ETF紧密跟踪恒生医疗保健指数，恒生医疗保健指数提供一项市场参考指标，反映在香港上市、主要 ...

对玻尿酸（透明质酸）、重组胶原蛋白两种流行医美原料的比较，引发了医美巨头华熙生物(688363)对 多家券商研报的公开"声讨"。 深夜发文"声讨" 5月17日晚23时许，华熙生物官方微信号发文《概念总在重演，科技永远向前》，将矛头指向多家券商 研报，相关研报提出胶原蛋白在皮肤修复、抗衰老和副作用等方面强于玻尿酸。 华熙生物在微信文章中表示，2022年开始，随着资本市场不断追求新的公司题材，重组胶原蛋白概念被 看似幸运地选中了。为了营造比透明质酸产业更大的预期，围绕某重组胶原企业的研报中，出现了大量 直接针对中国透明质酸产业的所谓"对比研究"。 包括华泰证券、安信证券等多家券商研报被华熙生物节选发在了上述文章中。华熙生物文章称，这些误 导性"结论"伴随着随后兴起的"玻尿酸过时论"被媒体和自媒体红人广泛传播，形成了资本市场与消费市 场的舆论共振，伤害了经几代人努力的、一个中国优势产业的市场转化基础。 华熙生物表示，透明质酸这一成分及相关产业在近几年资本市场的概念切换中遭遇了谎言与践踏，被描 述为"过时""不如某物质安全""不如某物质更具生物活性""不如某物质具备市场价值"……这些抹黑与受 操控的自媒体及网络上的虚 ...

Core Viewpoint - The medical beauty industry is experiencing a significant performance divergence among listed companies, driven by a shift from hyaluronic acid to collagen products, indicating a potential restructuring of industry value logic [1][3]. Group 1: Performance Analysis - In 2024, the performance of upstream medical beauty companies showed significant divergence, with companies like Juzi Biological and Jinbo Biological leading with high growth rates, while major hyaluronic acid players like Aimeike, Huaxi Biological, and Haohai Biological faced pressure [2][3]. - Aimeike's revenue growth slowed to 5.45%, the lowest since its listing, while Huaxi Biological's revenue declined by 11.61% and net profit dropped by 70.59% [3][5]. - Juzi Biological achieved revenue of 5.539 billion, a year-on-year increase of 57.2%, and a net profit of 2.062 billion, up 42.4% [5][7]. Group 2: Market Trends - The market for recombinant collagen products in China is projected to grow from 18.5 billion in 2022 to 108.3 billion by 2027, with a compound annual growth rate of 42.4% [7]. - Companies are increasingly entering the collagen market, including Aimeike and Huaxi Biological, which are exploring new opportunities in this segment [7][8]. - Huaxi Biological is developing proprietary recombinant human collagen products that have entered clinical trials, indicating a strategic shift towards innovative product development [7].

Core Insights - The analysis focuses on the financial performance of 17 representative listed companies in the daily chemical skincare industry, highlighting the significant disparity between sales gross margin and net profit margin [1][2]. Group 1: Financial Performance - In 2024, nearly 80% of the selected companies reported a sales gross margin exceeding 50%, with some companies achieving gross margins over 75% [1][2]. - The industry shows a trend of high gross margins but low net profit margins, with 70% of companies having net profit margins below 15% [1][2]. - The top three companies in terms of sales gross margin are Jinbo Biological (92.02%), Juzhi Biological (82.09%), and Fulejia (81.73%) [2]. Group 2: Sales Net Margin Analysis - The leading companies in sales net margin are Jinbo Biological (50.68%), Juzhi Biological (37.22%), and Fulejia (32.78%) [4]. - Companies such as Jiaheng Household Chemicals (-2.57%), Shanghai Household Chemicals (-14.67%), and Yixian E-commerce (-20.9%) exhibit significantly low net profit margins [4]. Group 3: Industry Challenges - The high sales expenses in the daily chemical skincare industry are identified as a primary reason for the low net profit margins, as substantial marketing costs erode profits [2]. - Qing Song Co. has the lowest sales gross margin at 17.42%, attributed to its positioning as an OEM, facing intense competition from thousands of domestic cosmetic OEMs [6]. - Yixian E-commerce's negative net profit margin of -20.9% is linked to ongoing losses and high marketing expenditures [6].

Group 1 - The Hang Seng Medical Index ETF has shown significant liquidity with a turnover of 1% and a transaction volume of 2.6148 million yuan, with an average daily transaction volume of 27.4616 million yuan over the past month [2] - The ETF's scale has increased by 28.6087 million yuan in the past month, ranking first among comparable funds, with a share increase of 12 million units in the last two weeks, also the highest among peers [2] - In terms of capital inflow, the ETF has seen net inflows on 5 out of the last 8 trading days, totaling 14.5271 million yuan [2] - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is 23.4, which is in the 4.36% percentile over the past year, indicating a valuation lower than 95.64% of the time in the past year, suggesting historical low valuations [2] - The top ten weighted stocks in the Hang Seng Medical Healthcare Index account for 57.09% of the index, including companies like WuXi Biologics and BeiGene [2] Group 2 - Since the reform of new drug research and development policies in 2015, China's innovative drug industry has developed a strong ecosystem, integrating excellent resources in preclinical and clinical stages, which has gained recognition from multinational corporations (MNCs) [3] - The pharmaceutical and biotechnology sector's Q1 2025 financial reports show stable revenue and profit performance, with notable improvements in certain sub-industries, indicating a return of market enthusiasm for the sector [3] - There is a recommendation to focus on international biotech companies, revaluation of innovative pipelines in generic companies, and companies in the CXO industry with significant order and operational improvements [3] - Investors without stock accounts can access investment opportunities in the Hong Kong medical sector through the Hang Seng Medical Index ETF linked fund (018433) [3]

Investment Rating - The report maintains an "Overweight" rating for the industry [4][6]. Core Insights - The 618 promotional event has been advanced, with Tmall's pre-sale period shortened compared to the previous year's Double Eleven event. The first wave of Tmall's 618 sales runs from May 13 to May 26, 2025, with a pre-sale deposit payment phase from May 13 to May 16, and a final payment and early purchase phase from May 16 to May 26. This is a 7-day advance compared to last year's 618 event and a 4-day reduction compared to last year's Double Eleven pre-sale period [2][11]. - The promotional mechanisms have been simplified, with Tmall and JD.com eliminating cross-store discounts and increasing platform subsidies. Tmall's official discounts range from 15% to 50%, and the number of coupons issued to 88VIP members has increased significantly from 2 to 6 compared to last year [2][12]. - The first hour of sales in Li Jiaqi's live stream saw a GMV increase of over 10% year-on-year, with notable performances from domestic brands such as Proya and Kefu Mei [3][15]. Summary by Sections 1. 618 Promotional Event - The promotional event's schedule has been advanced, with Tmall's pre-sale period shortened compared to the previous year [2][11]. - JD.com has canceled the pre-heating period, maintaining the same sales period as last year [2][11]. 2. Li Jiaqi's Live Stream Sales Performance - The first hour of the "Explosive Beauty Festival" in Li Jiaqi's live stream saw a GMV increase of over 10% year-on-year, with multiple brand collaborations [3][15]. - Domestic brands such as Proya and Kefu Mei performed exceptionally well during the first day of sales [3][16]. 3. Tmall 618 Pre-sale Rankings - Proya ranked first in the beauty sales during the first four hours of Tmall's pre-sale, with Kefu Mei entering the top three [3][21]. - The rankings indicate a strong performance from domestic brands, with Proya maintaining its leading position and Kefu Mei rising three spots [3][21].

Core Insights - The article highlights the achievements of Fan Daidi, a prominent figure in the biotechnology sector, who has transitioned from academia to becoming a billionaire entrepreneur through her innovations in collagen production [1][10]. Group 1: Background and Education - Fan Daidi was born into a rural family in Shaanxi and aspired to be a doctor but shifted to chemical engineering due to vision issues [5]. - She became the first female PhD in China's bio-chemical engineering field and returned to Northwest University to start her research career with limited funding [5][6]. Group 2: Innovations and Business Development - In 2000, she successfully produced human-like collagen using genetic engineering, leading to the first patent in this area in China [7]. - This innovation addressed issues related to animal-derived collagen, such as viral risks and immune rejection, and laid the foundation for her company, Juzi Biotechnology [7][8]. Group 3: Company Performance - Juzi Biotechnology achieved over 10 billion yuan in cumulative sales by 2022, establishing itself as a leader in the collagen market [8]. - The company's revenue surged from 900 million yuan in 2019 to 5.5 billion yuan in 2024, with net profits increasing from 550 million yuan to 2.06 billion yuan during the same period [14]. Group 4: Personal and Professional Identity - Fan Daidi holds significant stakes in Juzi Biotechnology and another company, Triangle Defense, with a combined market value of approximately 443 billion yuan [10][13]. - Despite her wealth, she continues to serve as a strict mentor at Northwest University, balancing her roles as an academic leader and a successful entrepreneur [16][17].

Core Viewpoint - The article highlights the rapid growth and competitive landscape of the recombinant collagen protein industry, focusing on two key players: Juzhi Biotechnology and Jinbo Biotechnology, both of which have achieved significant market milestones and financial success in recent years [1][2][5]. Company Overview - Juzhi Biotechnology was established in 2000 and specializes in the research, production, and sales of recombinant collagen and other bioactive components. It went public on the Hong Kong Stock Exchange in November 2022, becoming the first stock in the recombinant collagen sector listed there [4][5]. - Jinbo Biotechnology was founded in 2008 and went public on the Beijing Stock Exchange in 2023, marking it as the first stock in the recombinant collagen sector listed on that exchange [1][5]. Financial Performance - In 2024, Juzhi Biotechnology reported a revenue of 5.539 billion yuan, a year-on-year increase of 57.2%, while Jinbo Biotechnology achieved a revenue of 1.443 billion yuan, with a remarkable growth rate of 84.92% [8]. - Juzhi Biotechnology's adjusted net profit was 2.152 billion yuan, up 46.5% year-on-year, and Jinbo Biotechnology's net profit reached 732 million yuan, soaring by 144.27% [8]. - Both companies maintained high gross margins, with Juzhi Biotechnology at 82.09% and Jinbo Biotechnology at 92.02% in 2024 [8]. Market Trends - The recombinant collagen market in China is projected to grow from 18.5 billion yuan in 2022 to 108.3 billion yuan by 2027, reflecting a compound annual growth rate (CAGR) of 42.4% [6]. - The increasing consumer demand and advancements in biotechnology are driving the rapid development of the recombinant collagen industry [6]. Competitive Landscape - The industry is becoming increasingly competitive, with established players like Huaxi Biotechnology and Aimeike entering the recombinant collagen market. New entrants are also attempting to reshape the market dynamics [8]. - Juzhi Biotechnology's revenue heavily relies on its core brand, Kefu Mei, which contributes over 80% of its total revenue [9]. Challenges and Risks - Juzhi Biotechnology faces challenges due to its reliance on a single brand and an increasing dependence on online sales channels, which accounted for 71.6% of total revenue in 2024 [9]. - Jinbo Biotechnology also has a high revenue concentration, with 78.17% of its revenue coming from a single medical device product line [10]. - Both companies are navigating a competitive environment where maintaining market position and expanding product lines are critical for future growth [11][14].

Core Insights - The topic of "Northwest University Vice President Fan Daidi becomes the richest person in Shaanxi" has gained significant attention on social media, highlighting the wealth of Fan Daidi and her husband Yan Jianya, who own two listed companies: Juzhi Biotechnology and Triangle Defense [2] - According to the 2025 Hurun Global Rich List, Fan Daidi and her husband have a combined net worth of 31.5 billion yuan, surpassing other notable figures in the region [2] Company Overview - Juzhi Biotechnology, founded in 2000, specializes in the research, production, and sales of recombinant collagen and other bioactive components, and was listed on the Hong Kong Stock Exchange in November 2022 [3][4] - Fan Daidi, a co-founder of Juzhi Biotechnology, served as the executive director until July 2023 and has a long-standing affiliation with Northwest University, where she has held various academic positions [3][4] Market Dynamics - The recombinant collagen market is experiencing rapid growth, with a projected market size increase from 18.5 billion yuan in 2022 to 108.3 billion yuan by 2027, reflecting a compound annual growth rate (CAGR) of 42.4% [4] - Both Juzhi Biotechnology and Jinbo Biotechnology are showing high growth rates, with Juzhi's revenue reaching 5.539 billion yuan in 2024, a year-on-year increase of 57.2%, while Jinbo's revenue grew by 84.92% to 1.443 billion yuan [5] Financial Performance - Juzhi Biotechnology reported an adjusted net profit of 2.152 billion yuan in 2024, up 46.5% year-on-year, while Jinbo's net profit surged by 144.27% to 732 million yuan [5] - Both companies maintain high gross margins, with Juzhi's gross margin at 82.09% and Jinbo's at 92.02% in 2024 [6] Competitive Landscape - The competition in the recombinant collagen sector is intensifying, with established players like Huaxi Biotechnology and Aimeike entering the market, alongside new entrants like Hangzhou Meiliu Biotechnology, which has significantly reduced production costs [6][9] - Juzhi Biotechnology's revenue heavily relies on its core brand, Kefu Mei, which accounts for over 80% of its revenue, and the company is increasingly dependent on online sales channels, which constituted 71.6% of total revenue in 2024 [6][7] Product Development Challenges - Juzhi Biotechnology has plans to enter the recombinant collagen injection market, with two products expected to be approved in 2024, but currently, its registration is limited to dressing products [7][8] - Jinbo Biotechnology has achieved breakthroughs in the third-class medical device sector, holding all three existing registrations for recombinant collagen medical devices in China, but also faces challenges with revenue concentration [8][9]